Diabetic patients have an increased risk of foot ulcers, and glycation of collagen may increase tissue 39 stiffness. We hypothesized that the level of glycemic control (glycation) may affect Achilles tendon 40 stiffness, which can influence gait pattern. We therefore investigated the relationship between 41 collagen glycation, Achilles tendon stiffness parameters and plantar pressure in poorly (n = 22) and 42 well (n = 22) controlled diabetic patients, including healthy age matched (45-70 yrs) controls (n = 43 11). There were no differences in any of outcome parameters (collagen cross-linking or tendon 44 stiffness) between patients with well-controlled and poorly controlled diabetes. The overall effect of 45 diabetes was explored by collapsing the diabetes groups (DB) compared to the controls. Skin 46 collagen cross-linking lysylpyridinoline (LP), hydroxylysylpyridinoline (HP), (136%, 80%, P < 47 0.01) and pentosidine concentrations (55%, P < 0.05) were markedly greater in DB. Furthermore, 48
Introduction 61
Pathological conditions of the feet remain an extensive clinical problem in persons with diabetes 62 (6), and advanced diabetes ulcerations of the forefoot are the main reason for lower extremity 63 amputations (20) . In fact, approximately 25% of all hospital admissions of diabetic patients 64 encompass pathological conditions of the feet, and about 15% of all diabetes patients will develop a 65 foot ulcer (20) . In addition to this, Achilles tendon problems are more pronounced in patients with 66 diabetes (1), but it is unknown to what extent this is due to altered tendon tissue properties in 67 diabetes, or rather is secondary to altered gait pattern or skin ulcers. 68
Patients with poorly controlled diabetes have elevated plasma glucose concentrations, and 69 this is associated with the accumulation of AGE (Advanced Glycation Endproducts) derived cross-70 links in various collagenous tissues such as skin, via the Maillard reaction (37). There is evidence 71 that compromised tissue function is a consequence of such increases in AGE cross-linking (4, 37-72 39, 46) . In vitro experiments have shown that glycation increases tendon stiffness and strength (3, 73 26, 27, 45) . Increased collagen and tendon stiffness, due to the accumulation of intermolecular AGE 74 cross-links, has been proposed as a concomitant factor in the development of pathological foot 75 conditions in diabetes (23, 41) , but reports on AGE accumulation in the human diabetic tendon is 76 sparse (24, 52) . 77
Evidence of mechanical changes in diabetic tendons is currently inconclusive, since the 78 effect of diabetes on animal tendon has been reported to result in increased (2, 35, 42) or decreased 79 (7, 12, 18 ) stiffness properties. In addition, it has not been investigated if the quality of glycemic 80 control in diabetic patients affects AGE cross-linking and tendon stiffness. At the micro-structural 81 level, the extent to which tendon collagen fibrils are affected by diabetes is also sparsely 82 investigated (23). A few animal studies (3, 43) and a single human study (23) have demonstrated 83 significant changes in tendon fibril morphology (increased fibril density and decreased mean fibril 84 area). The biomechanical consequences of theses changes in terms of potential alterations in tendon 85 tissue stiffness currently remain unknown. 86
The influence of Achilles tendon stiffness on gait patterns in diabetic patients is unknown, 87 but elevated Achilles tendon stiffness may well decrease dorsiflexion capacity of the ankle joint, 88 and reduced dorsiflexion has been reported to increase forefoot loading (17). Moreover, excessive 89 plantar pressure has been shown to result in elevated tissue breakdown and delayed wound healing 90 in the foot (41) and could be a risk factor for diabetes related pathological foot conditions (51) . 91
Therefore, the purpose of the present study was to investigate the hypothesis that poorly controlled 92 diabetes is associated with greater accumulation of AGE cross-links, greater tendon stiffness and 93 altered gait pattern compared to well-controlled diabetes, that may lead to development of foot 94
ulcers. This hypothesis was tested by examining the concentration of enzymatic and non-enzymatic 95 collagen cross-links in skin and tendon, Achilles tendon stiffness, and the modulation in plantar 96 pressure during gait in poorly and well-controlled diabetic patients compared to healthy age-97 matched controls. 98
99

Methods
100
The present cross-sectional study was designed to compare the effect of glycemic control (based on 101 2 year average HbA1c) in two groups of male diabetic patients (type I and type II) with either well 102 (n = 22, HbA1c < 7.5%; WCD) or poorly-(n = 22, HbA1c > 9%; PCD) controlled diabetes. The 103 number of type 1 diabetic patients was: 1 in WCD and 3 in PCD. Subject characteristics are shown 104 in Table 1 . A smaller healthy control group was also included to provide baseline healthy 105 characteristics (n = 11, HbA1c < 6%; CON). Subjects were matched for age (45-70 years) 
Blood Sampling 121
Blood samples of 10 mL were collected before the test day and sent for standard clinical blood tests 122 for triglycerides, high and low-density lipoprotein cholesterol (HDL and LDL), total cholesterol and 123
HbA1c as a measure of mean glucose load over the previous 2-3 months (14, 40) . For the diabetic 124 patients (WCD, PCD), the two-year average HbA1c was also determined based on data from their 125 medical records (3-4 measurements). 126
127
Biopsy Sampling 128
After biomechanical testing was performed (details given below) biopsy specimens of the Achilles 129 tendon were obtained in the non-dominant leg at the distal end of the tendon 4 cm proximal to the 130 calcaneus. Using ultrasound imaging, the biopsy site was marked on the skin and under local 131 anesthetic (1% lidocaine) the biopsy was obtained with a 16 gauge Bard Monopty triggered biopsy 132 instrument (C. R. Bard Inc, Covington GA). Skin biopsies were performed using a 4 mm biopsy 133 punch (Miltex, York PA) in the gluteal region under local anesthetic (1% lidocain). Both tendon 134 and skin biopsies were immediately frozen in liquid nitrogen for cross-link analysis, and a small 135 segment from the tendon was also placed in 0.05 M phosphate buffered 2% glutaraldehyde for 136 electron microscopy. 137
138
Collagen Cross-links 139
The concentrations of enzymatic cross-links lysylpyridinoline (LP) and hydroxylysylpyridinoline 140 (HP), and non-enzymatic AGE cross-link pentosidine in the biopsy samples were quantified as 141 previously described (8, 32) . In brief, the tendon biopsy was hydrolysed in 6 M HCl and run on a 142 reversed-phase high performance liquid chromatography column with detection by 143 autofluorescence. The cross-link content was normalized to total collagen content based on 144 hydroxyproline measurement by 4-dimethylaminobenzaldehyde color reaction after oxidation, as 145 previously described (8, 32). Three tendon and 5 skin biopsies were lost during processing for 146 cross-link analysis. 147
148
Electron Microscopy 149
Transmission electron microscopy was performed as previously reported (30, 32 Details of the tendon morphology measurements have previously been published (29). In brief, the 160 subject was sitting with the hip, knee and ankle at 90º and using a 100 mm long ultrasound probe 161 the full length of the free tendon from its insertion on the calcaneus to its fusion with the soleus 162 muscle was imaged in B-mode. Using the ultrasound "shadow" of a long needle, the calcaneus and 163 soleus insertions were marked on the skin with a permanent marker. Three evenly spaced marks 164
were placed between the two ends (proximal, mid and distal), and axial ultrasound images were 165 recorded at each point for determining tendon cross-sectional area (CSA) as previously described 166 (29). The average tendon CSA was calculated and used for analysis. The paired student's t-test 167 (systematic error), Pearson correlation coefficient (strength of relationship) and typical error percent 168 for duplicate measures within day were 0.64, 0.93 and 3% for proximal, 0.70, 0.90 and 4% for mid 169 tendon, and 0.57, 0.90 and 4% for distal tendon. The Achilles tendon moment arm was determined 170 as the distance from the foot axis of rotation (mean of medial and lateral malleoli) to the tendon line 171 of action (mid line between calcaneus and soleus insertion) as previously described (29) . 172
173
Achilles Tendon Mechanical Properties 174
Mechanical properties of the Achilles tendon were assessed using a method that has previously been 175 described and validated in detail (29). In brief, subjects were seated in a rigid chair with the hip, 176 knee and ankle at 90º. The foot was resting on a footplate with the foot axis of rotation vertically 177 above the plate axis of rotation (see Figure 1) . The knee was immobilized by a steel cross-bar to 178 prevent lower limb motion (29). A load cell fixed to the footplate was used to measure the plantar 179 flexor moment. Electromyography (EMG) electrodes were attached to the tibialis anterior and 180 soleus muscles to monitor muscle activation and correct for antagonist co-activation as previously 181 described (29). Achilles tendon deformation was monitored using B-mode ultrasound imaging 182 (Hitatchi EUB-6500) with a 100 mm long 10 MHz probe positioned along the tendon to visualize 183 the insertion at the calcaneus and soleus. 184
Achilles tendon mechanics were assessed during slow (10s) were also determined at the largest common tendon force observed across participants. To avoid the 196 highly nonlinear toe region commonly observed in tendon at low load, 7 participants (all from the 197 diabetic groups) with particularly low force production were omitted from this comparison. The 198 decision to omit the data points in these 7 participants were made prior to running any between-199 group analyses. The selected common tendon force level was 1815 N. Five participants did not 200 complete all morphology and mechanical tests due to logistical reasons. 201
202
Gait Analysis 203
Load distribution on the foot during walking was determined using a pressure plate (4 sensors/cm 2 , 204
Emed, Novel, Germany) integrated into a wooden walking path. Subjects were instructed to walk 205 normally along the path and the pressure plate was hit at the third step after start. The mean pressure 206 distribution during 5 steps from each foot was calculated and pressure distribution was assessed by 207 the forefoot/rearfoot peak plantar pressure ratio (PPP-Ratio). Two participants did not complete gait 208 analyses due to logistical reasons. 209
210
Data Reduction and Statistics 211
The study was initially powered for the comparison of the WDC and PDC groups, with the healthy 212 controls (CON) included only as a baseline. Tendon stiffness was considered the primary outcome 213 and sample size was determined to be 21 for an effect size of 0.2 with 80% power and a 214 significance level of 5%. Differences between WCD and PCD were determined by an unpaired two-215 tailed Student's t-test corrected for unequal variances. No differences were observed between the 216 two diabetic groups for any of the outcome variables related to the hypothesis. For this reason it was 217 decided to also report findings relative to the healthy group as a more exploratory approach, in spite 218 of this group being underpowered. Acknowledging that the study is underpowered, we also report 219 some near-significant trends as a basis for future investigation. Diabetic patients were combined 220 into a merged diabetes (DB) group and subsequently compared to CON using unpaired two-tailed 221
Students t-tests corrected for unequal variances. Pearson product-moment correlation analysis was 222
used to analyze the strength of relationships between variables within the merged diabetes group 223 (DB). P < 0.05 was considered significant. Results are reported as mean ± standard error (SE) 224 unless otherwise reported. Student's t-tests were performed using Excel for Mac 2011 (Microsoft 225 corporation) while all correlation analysis was performed using Prism 6 (Graphpad Software Inc.). 226
227
Results
228
Subject characteristics 229
Diabetes duration was not different between the WCD and PCD groups. HbA1c concentration was 230 higher in PCD compared to WCD, both at present (8.9 ± 1.7% vs. 7.2 ± 0.9%, P < 0.01) and as 2-231 year average (9.4 ± 1.4% vs. 6.9 ± 0.5%, P < 0.01). Subject characteristics are shown in Table 1 . 232
Body mass was greater in DB compared to CON (P < 0.01). The difference in IPAQ score was not 233 significant between the groups. 234 235
Collagen cross-linking 236
Tendon collagen cross-link data are shown in Table 2 . None of the parameters collagen, 237 pentosidine, HP and LP concentration, differed significantly between DB and CON. Tendon 238 pentosidine was positively related to age (r = 0.42, P < 0.01). Skin collagen cross-link data are 239 shown in Table 2 . In contrast to tendon, skin pentosidine (P < 0.05), LP (P < 0.01) and HP (P < 240 0.01) concentrations were higher in DB than CON. Two year HbA1c correlated with skin HP (r = 241 0.34, p < 0.05) and pentosidine (r = 0.31, p < 0.05). 242
243
Collagen fibril characteristics 244
Collagen fibril data are shown in Table 2 . Tendon fibril density was greater in DB compared to 245 CON (P < 0.05). 246 247
Achilles Tendon Morphology 248
The Achilles tendon moment arm was greater in DB compared to CON (4.26 ± 0.07 vs. 3.94 ± 0.10 249 cm, P < 0.05). However, no other differences were observed between DB and controls with respect 250 to average Achilles tendon CSA (0.73 ± 0.02 vs. 0.79 ± 0.03 cm 2 , P = 0.23) or free Achilles tendon 251 length (6.5 ± 0.2 vs. 6.1 ± 0.4 cm, P = 0.47). 252
253
Mechanical Tendon Properties 254
Mechanical properties of the Achilles tendon at maximum force are shown in Table 3 . DB did not 255 differ from CON although there was a trend toward reduced Achilles tendon strain in DB compared 256 to controls (effect size 0.9%, P = 0.075). Mechanical properties of the Achilles tendon at largest 257 common force are shown in Table 3 . DB had higher Achilles tendon modulus at common force than 258 CON (P < 0.001). 259
260
Gait Analysis 261
Gait data are shown in Table 3 . DB demonstrated greater forefoot/rearfoot PPP-Ratio than CON (P 262
To the best of our knowledge the present study is the first to investigate if diabetes in humans is 266 associated with greater Achilles tendon glycation and stiffness, and altered gait. In contrast to our 267 initial hypothesis, we could not demonstrate any differences in collagen cross-linking or 268 biomechanical Achilles tendon stiffness between patients with well-controlled and poorly-269 controlled diabetes. However, in skin collagen cross-linking (HP, LP and pentosidine 270 concentrations) was markedly greater in diabetic patients compared to healthy age-matched 271 controls. Furthermore, Achilles tendon modulus, which represents the material stiffness after 272 accounting for tendon dimensions, was higher in diabetic patients compared to controls. Notably, 273 diabetic patients also demonstrated higher forefoot/rearfoot peak plantar pressure ratio (PPP-ratio) 274 indicating a more forward distributed loading pattern on the foot. This difference in foot pressure 275 distribution may contribute to the development of foot ulcers in diabetic patients. These findings 276 lend some support to the hypothesis that diabetes leads to increased stiffness in the Achilles tendon 277 and an elevated forefoot pressure. 278
279
Collagen cross-linking 280
In diabetes there is an increased rate of non-enzymatic formation of AGE cross-links, which may 281 also affect the protein structure and function of connective tissue such as tendon and skin. In 282 collagen one such cross-link is pentosidine, and in the present study the concentration of 283 pentosidine was greater in skin of diabetic patients, although somewhat surprisingly not elevated in 284 the Achilles tendon. In agreement with the present skin data, previous work on experimental animal 285 and human skin composition also show increased pentosidine concentration (16, 37) and other 286 glycation products with diabetes (5, 13). In contrast, data on cross-links in the diabetic tendon are 287 scarce. A greater glycation in the tendon of diabetic human digastric muscle and diaphragm has 288 been shown, although pentosidine was not measured specifically (24, 52). In diabetic animals, 289 increased glycation of tendon has also been reported (35, 42) . The difference between tendon and 290 skin data in the present study may relate to differences in tissue turnover. Tendons have very slow 291 turnover, and may even be maintained throughout adult life (25), while skin has a much more rapid 292 turnover rate (50), as also indicated by the lower pentosidine concentrations presently observed in 293 skin biopsies compared to tendon biopsies. Consequently, pentosidine in tendon most likely 294 represent an average over a longer time period than that of skin, and therefore the relative effect of 295 the period with diabetes may be smaller in tendon tissue. 296
Another factor potentially affecting the pentosidine concentration in Achilles tendons is the 297 level of physical activity of the subjects. It has recently been shown that the pentosidine 298 concentration of the patellar tendon is reduced in elderly life-long regular endurance runners 299 (master athletes) compared to sedentary controls (9), and that resistance training can reduce 300 pentosidine concentration in patellar tendons (28). If loading of tendons can ameliorate AGE 301 accumulation, it may also explain why greater AGE accumulation was observed in the diabetic 302 digastric tendon as previously mentioned, since this tendon is not weight bearing. 303
The present study also revealed markedly greater HP and LP concentrations in the skin of 304 diabetic patients compared to healthy controls. The concomitant greater in glycation and enzymatic 305 cross-links is in agreement with previous reports on skin collagen in diabetic conditions (5). 306
Conversely, in the Achilles tendon we did not observe a similar greater cross-linking (HP and LP (P 307 = 0.10)) with diabetes, which to our knowledge has not previously been examined in human 308 diabetic tendons. A simultaneous greater HP, LP and pentosidine with aging have been 309 demonstrated in the human patellar tendon (8). Based on the 'synchronized' changes in non-310 enzymatic and enzymatic cross-links reported in both diabetes and aging, it is reasonable to 311 speculate that some mechanistic link(s) may exist between the two cross-linking processes. The 312 finding that serum two-year average HbA1c and skin pentosidine in the present study demonstrated 313 a weak relationship (r = 0.31, P < 0.05) while this was not the case in the tendon (r = 0.03, P = 314 0.84). This may indicate that the skin tissue is subjected to a systemic effect of AGEs with less 315 protection by physical activity and mechanical loading, which thereby could lead to greater 316 accumulation of non-enzymatic cross-links in skin compared to tendon. Despite superior glycemic 317 control (Hb1Ac) in WCD compared to PCD there were no differences in any of the collagen cross-318 linking parameters examined, which is in agreement with observations by Lyons et al. who reported 319 similar skin pentosidine content in type 1 diabetic patients with better glycemic control (34). 320 Monnier et al (37) reported an approximately 20% lower skin pentosidine in diabetic patients with 321 improved glycemic control and considering the absolute difference observed in the present study, 322 there is in fact a similar difference, so the lacking effect may reflect a sample size issue. 323
324
Collagen fibril morphology 325
Some studies have reported on tendon microstructural changes in diabetes. Both animal and human 326 studies have reported greater collagen fibril density and decreased mean fibril area (3, 23, 43) . The 327 present study revealed a 25% higher fibril density in diabetic patients compared to controls. 328 Furthermore, mean fibril diameter and mean fibril area tended (P = 0.096) to be reduced (11%) in 329 diabetic patients compared controls, confirming previous findings (3, 23, 43). Why diabetic tendon 330 collagen fibrils display higher fibril density is unknown. It has been speculated that closer packing 331 density could be a result of AGEs binding together collagen fibrils (3, 33). Another mechanism 332 could be that the higher density is a compensating mechanism for a lower mean fibril diameter 333 thereby maintaining total collagen content and volume fraction in agreement with our findings. 334
However these mechanisms need to be explored further. 335
336
Achilles Tendon Mechanical Properties 337
In the present study we observed no difference in Achilles tendon mechanics expressed in absolute 338 terms between WCD and PCD, however a 54% greater Young modulus was observed in diabetic 339 patients compared to healthy controls, indicating that qualitative differences exist between diabetic 340 and healthy Achilles tendon tissue. Diabetes has previously been associated with mechanical 341 changes in different tissues including tendon. In experimental diabetic animals greater stiffness has 342 been extensively reported in non-weight bearing rat-tail tendon (2, 19, 21, 22, 35, 42, 53) and knee 343 ligaments (15). Likewise, in various human non-weight bearing connective tissue such as blood 344 vessels (49) and the lens of the eye (44), it has been reported that diabetes induces greater tissue 345 stiffness. A modest increased stiffness has also been demonstrated in weight bearing diabetic canine 346 patellar tendon under long-term insulin therapy (31). In contrast, lower stiffness of the Achilles 347 tendon has been reported in several experimental diabetic animal studies (7, 12, 18) , and this may 348 be attenuated by weight bearing physical activity (11). It was recently shown that Achilles tendon, 349 strains are less during walking in human diabetic patients than in controls, which may indicate that 350 greater tendon stiffness could be related to observed differences in the gait pattern of these patients 351 (10). To our best knowledge the present study is the first to directly measure the mechanical 352 properties of human diabetic Achilles tendons in vivo. Our data show a markedly (54%) higher 353
Achilles tendon material stiffness (modulus) compared to controls, however, absolute tendon 354 stiffness was not significantly different despite it was numerically 27% greater in diabetic patients. 355
The difference between the modulus and stiffness lies in the tendon dimensions, with the diabetic 356 tendon towards a greater tendon length and reduced cross-sectional area (neither significant), which 357 counteracts the greater material stiffness. It is possible that the Achilles tendon dimensions of 358 diabetic patients may have adapted to counteract increased material stiffness in order to maintain 359 functional stiffness, but this hypothesis cannot be addressed by the data obtained in the present 360 study. 361
Cross-linking by AGEs is the likely mechanism underpinning tissue stiffening with diabetes 362 (38), and AGE cross-links have been shown to increase tendon stiffness in vitro, where tendon is 363 incubated with a reducing sugar (26, 27, 45) . In the present study the material stiffness of the 364
Achilles tendon was greater with diabetic patients, however no differences were observed in 365 pentosidine or HP, LP cross-link concentrations. In addition, collagen content also did not differ 366 between diabetic patients and healthy controls. The diabetic patients had a higher fibril density, but 367 due to their tendency (P = 0.096) to toward a lower fibril size the total volume fraction, and thus the 368 load bearing cross-sectional area was unaltered. 369
370
Gait 371
In the present study, diabetic patients demonstrated higher forefoot/rearfoot PPP-ratio indicating 372 increased forefoot loading during walking. This finding is in agreement with our initial hypothesis. 373
A forward shift in pressure could be caused by an increased ankle joint stiffness; however, the 374 hypothesized relation to absolute Achilles tendon stiffness was not observed. As previously 375 discussed, the weight bearing nature of the Achilles tendon may render it less susceptible to diabetic 376 changes than other tissues crossing the joint. Since diabetes is a systemic disease these other tissues 377 are likely also affected and may contribute to overall joint stiffness. One concern could be that the 378 difference in tendon moment arm observed between the two subject groups would influence these 379 findings, however, the moment arm was not correlated to either forefoot/rearfoot PPP-ratio or 380 tendon modulus, respectively. However, the potential influence of the Achilles tendon should not 381 be completely disregarded, since the modulus was greater and there were tendencies for both 382 greater absolute stiffness and reduced strain, and as such, a lack of sensitivity may have prevented. 383
Stiffening of the Achilles tendon material properties combined with the observed tendency for 384 decreased tendon strain (potentially causing reduced dorsiflexor ROM during the late stance phase) 385 could per se cause an increased magnitude of forefoot loading, and any systemic glycation effect 386 would likely also stiffen other connective tissues surrounding the joint. Notably, reduced 387 dorsiflexion ability has been shown to increase peak plantar pressure during walking (17) while 388 excessive plantar pressure has been shown to result in accelerated tissue breakdown and delayed 389 wound healing (41). 390
391
Study Limitations 392
The present investigation is a cross-sectional case-control study and, therefore, has inherent 393 limitations. Furthermore, while a fairly large number of diabetic patients were recruited, a larger 394 number of control subjects would have improved the statistical strength. In the present study the 395 only measured AGE marker was pentosidine, which constitutes a small fraction of AGE cross-links 396 (47). Even though pentosidine is reported to correlate well with diabetic tissue complications (48), 397 total AGE fluorescence (36, 48) and with more abundant AGEs such as carboxymethyllysine 398 (CML)(4), it is possible that investigating other AGE targets (47) could have provided additional 399 information to help explain the greater Achilles tendon mechanics in our diabetic patients. 400
In vivo mechanical measurements are also affected by several limitations. The tendon load 401 is estimated from external moments, and while muscle activation was partly accounted for by EMG 402 measurements, there are still uncertainty in such measures. In addition, the CSA used for 403 determining tendon stress was measured by ultrasound, which is less precise than for example MRI. 404
Finally, tendon deformation is also determined with ultrasound in 2D and some uncertainty may be 405 present due to out of plane motion. These factors combine to increase the variance of the 406 measurements, but should affect the groups equally. 407 There were differences in the baseline characteristics of the two groups, which could affect 408 the outcome. The diabetic group had a higher body mass, and as would be expected peak plantar 409 pressure did correlate with body mass (r = 0.23, P = 0.1), the forefoot/rearfoot PPP-ratio was not 410 correlated to body mass (r = 0.06, P = 0.66). Furthermore, tendon stiffness correlated with body 411 mass (r = 0.34, P = 0.03), but body mass was not linked to modulus (r = 0.22, P = 0.14). 412
Moreover, the moment arm in diabetic group was higher than in controls. In the present study, the 413 method used to determine moment arm may have some limitations that could have influenced our 414 results. Using e.g. x-ray would have been more precise. However, we were not able demonstrate 415 that the difference in moment arm correlated with the outcome parameters (Forefoot/rearfoot PPP-416 ratio: r = -0.10, P = 0.48, Modulus: r = -0.16, P = 0.30). In addition, the higher moment arm in 417 the diabetic group would have underestimated modulus and thereby cannot be the reason for the 418 observed increase in the diabetic group. To our knowledge there is no evidence that diabetes results 419 in altered moment arm and so we would believe that the difference observed in the present study is 420 spurious. Altogether, if we include mass and moment arm as confounding factors in an ANOVA, 421 the main findings of increased forefoot/rearfoot PPP-ratio and modulus in the diabetic group remain 422 significant. 423
424
Conclusions 425
For the first time it was demonstrated that irrespective of hyperglycemia severity Achilles tendon 426 material stiffness was greater in diabetic patients compared to age-matched healthy controls. The 427 finding that well and poor glycemic controlled diabetic patients did not differ in terms of 428 biomechanical Achilles tendon properties was in contrast to our initial hypothesis. Surprisingly, 429 collagen cross-linking also did not differ in the Achilles tendon of the diabetic patients compared to 430 that of controls. In contrast, when assessed in the skin HP, LP and pentosidine cross-link 431 concentrations were markedly greater in diabetic patients compared to controls. Furthermore, 432 diabetic patients showed higher forefoot/rearfoot PPP-ratio during walking, however, a direct 433 relation to increased Achilles whole tendon stiffness was not found, indicating that altered Achilles 434 tendon material stiffness and possibly also in other tissues (e.g skin and joint capsule) may 435 influence plantar pressure distribution during gait habitual walking. Collectively, our data suggest 436 that both the material stiffness of the Achilles tendon and foot pressure distribution are altered in 437 diabetic patients. Such changes in tendon material properties and loading may have implications for 438 the development of diabetic foot ulcers. 439
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Tendon Fibril Morphology
Number of Participants 18 22 40 10
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Mean fibril diameter (nm) 64 ± 4 65 ± 3 64 ± 2(*) P = 0.096
± 14
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Figure 1 619
The Achilles tendon stress-strain relationship based on largest common tendon force observed for 620 merged Diabetic patients (DB) and age-matched healthy controls. Data are given as mean ± SE. DB 621 showed higher Achilles tendon modulus than controls at highest common tendon force (P < 0.001). 
